Evaxion A/S

Company's own description on virk.dk

General Evaxion is a pioneering TechBio company based upon our proprietary AI platform, AI-Immunology™, which has been continuously developed and refined over the past 18 years. This validated and scalable platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccines for cancer and infectious diseases. We are planning to expand into autoimmune diseases as well. Based upon AI-Immunology™, Evaxion has developed a pipeline of preclinical and clinical R&D-programs, including therapeutic cancer vaccines (both personal and off-the-shelf) and prophylactic vaccines against bacterial and viral diseases with high unmet medical needs. We are committed to transforming patients’ lives by providing innovative and targeted treatment options. Our pipeline contains vaccines against pathogens for which no vaccines exist today; S. aureus, Group A streptococcus, N. gonorrhoeae and cytomegalovirus. Our purpose is simple: Saving and improving lives with AI-Immunology™ powered vaccines. We invest to fulfil this purpose and to create long-term value for our owners, patients and other stakeholders. As a business, we create and derive value both from our AI-Immunology™ platform and our pipeline of vaccine candidates under development. This sets us apart from traditional biotech companies basing their value only on development candidates and from tech companies with just a platform.